CT changes in a randomized trial comparing early therapies in an outpatient population at high risk of severe COVID19 disease

Abstract Although in vitro studies suggest that neutralization by monoclonal antibodies (mAbs) against SARS CoV2 Omicron sub lineages is reduced, in vivo virological response data are lacking. MONET (EudraCT: 2021–004188-28) was multi-centric phase 4 open-label parallel randomized clinical trial, co...

Descripció completa

Dades bibliogràfiques

Autors principals:	Ilaria Mastrorosa, Alessandro Cozzi-Lepri, Giulia Matusali, Francesca Colavita, Simone Lanini, Martina Rueca, Alessandra Oliva, Giulia Berno, Alessandra Vergori, Silvia Rosati, Jessica Paulicelli, Enrico Girardi, Emanuele Nicastri, Fabrizio Maggi, Andrea Antinori, Valentina Mazzotta, the MONET Clinical Trial Group
Format:	Artigo
Idioma:	Inglês
Publicat:	Nature Portfolio 2025-08-01
Col·lecció:	Scientific Reports
Matèries:	SARS coronavirus RCT Monoclonal antibodies Antiviral agents CT value Antibodies response
Accés en línia:	https://doi.org/10.1038/s41598-025-15641-1
Etiquetes:	Afegir etiqueta Sense etiquetes, Sigues el primer a etiquetar aquest registre!